US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration LOS ALTOS, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration’s (FDA’s) Office of Orphan Products Development (OOPD) granted orphan drug...

Study of Retrotope’s deuterated polyunsaturated fatty acid drugs published in The FEBS Journal LOS ALTOS, Calif. and TORONTO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Retrotope and collaborators, led by Dr. Brian Bennett of Queen’s University, have published a paper entitled “Deuterium-reinforced...